Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;38(10):1042-1055.
doi: 10.1016/j.healun.2019.08.001. Epub 2019 Aug 8.

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match

Daniel C Chambers  1 , Wida S Cherikh  1 , Michael O Harhay  1 , Don Hayes Jr  1 , Eileen Hsich  1 , Kiran K Khush  1 , Bruno Meiser  1 , Luciano Potena  1 , Joseph W Rossano  1 , Alice E Toll  1 , Tajinder P Singh  1 , Aparna Sadavarte  1 , Andreas Zuckermann  1 , Josef Stehlik  2 ; International Society for Heart and Lung Transplantation  1
Affiliations

The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match

Daniel C Chambers et al. J Heart Lung Transplant. 2019 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of adult lung transplants by year and procedure type (transplants: 1988–2017).
Figure 2
Figure 2
Major indications for adult lung transplantation by year (absolute number; transplants: 1990–2017). A1ATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; ILD-not IIP, interstitial lung disease-not idiopathic interstitial pneumonia.
Figure 3
Figure 3
Induction immunosuppression for adult lung transplant recipients (transplants: January 2005–December 2017). ALG, antilymphocyte globulin; ATG, anti-thymocyte globulin; IL-2R, interleukin-2 receptor.
Figure 4
Figure 4
Kaplan-Meier survival for adult lung transplant recipients by transplant era (transplants: 1992–June 2017). NA, not applicable.
Figure 5
Figure 5
Statistically significant categorical risk factors for 10-year mortality for adult lung transplant recipients with 95% CIs (transplants: 2000–June 2008, N = 18,673). CF, cystic fibrosis; CI, confidence interval; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disorder; CTD, connective tissue disease; DCD, donation after circulatory death; F, female; HR, hazard ratio; LAM, lymphangioleiomyomatosis; LCL, lower control limit; M, male; Retx, retransplantation; UCL, upper control limit.
Figure 6
Figure 6
Hazard ratio for 10-year mortality for adult lung transplant recipients by recipient and donor age (transplants: 2000–June 2008, N = 18,673). This model excludes size match. The reference for recipient age is 54 years and for donor age is 36 years.
Figure 7
Figure 7
Distribution of donor-recipient height difference for adult lung transplant recipients by procedure type and recipient diagnosis (transplants: January 2005–June 2018). A1ATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; ILD-not IIP, interstitial lung disease-not idiopathic interstitial pneumonia.
Figure 8
Figure 8
Kaplan-Meier survival within 1 year for adult lung transplant recipients by donor-recipient weight difference (transplants: January 1995–June 2017).
Figure 9
Figure 9
Kaplan-Meier survival within 5 years for adult lung transplant recipients by donor-recipient weight difference (transplants: January 1995–June 2013).
Figure 10
Figure 10
Kaplan-Meier survival within 1 year for adult lung transplant recipients by donor-recipient height difference (transplants: January 1995–June 2017).
Figure 11
Figure 11
Kaplan-Meier survival within 5 years for adult lung transplant recipients by donor-recipient height difference for (a) A1ATD/COPD, (b) CF, (c) IIP/ILD-not IIP, and (d) other diagnoses (double lung transplants: January 1995–June 2013). A1ATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; ILD-not IIP, interstitial lung disease-not idiopathic interstitial pneumonia.
Figure 12
Figure 12
Statistically significant categorical risk factors for 5-year mortality for adult lung transplant recipients with 95% CIs (transplants: 2005–June 2013, N = 27,023). This model includes size match. A1ATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; CI, confidence interval; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; F, female; HLA, human leukocyte antigen; HR, hazard ratio; IIP, idiopathic interstitial pneumonia; ILD-not IIP, interstitial lung disease-not idiopathic interstitial pneumonia; LCL, lower control limit; M, male; UCL, upper control limit.
Figure 13
Figure 13
Hazard ratio of 5-year mortality for adult lung transplant recipients by donor-recipient weight difference (transplants: 2005–June 2013, N = 27,023). The reference value for weight difference is 5 kg.
Figure 14
Figure 14
Hazard ratio of 5-year mortality for adult lung transplant recipients by donor-recipient height difference (transplants: 2005–June 2013, N = 27,203). The reference value for height difference is 2.4 cm.
Figure 15
Figure 15
Hazard ratio of 5-year mortality for adult lung transplant recipients by donor-recipient height difference and diagnosis interaction (transplants: 2005–June 2013, N = 27,023). A1ATD, alpha-1-antitrypsin deficiency; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; ILD-not IIP, interstitial lung disease-not idiopathic interstitial pneumonia.
Figure 16
Figure 16
Number of adult heart-lung transplants by transplant year.
Figure 17
Figure 17
Kaplan-Meier survival for adult heart-lung transplant recipients by transplant era (transplants: January 1992–June 2017). NA, not applicable.
Figure 18
Figure 18
Kaplan-Meier survival for adult heart-lung transplant recipients by major diagnosis (transplants: January 1992–June 2017). CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; IIP, idiopathic interstitial pneumonia; IPAH, idiopathic pulmonary arterial hypertension; NS, not significant; PH, pulmonary hypertension.
Figure 19
Figure 19
Kaplan-Meier survival for adult heart-lung transplant recipients within 5 years by donor-recipient height difference (transplants: January 1992–June 2013). NS, not significant.
Figure 20
Figure 20
Kaplan-Meier survival for adult heart-lung transplant recipients within 5 years by donor-recipient weight difference (transplants: January 1992–June 2013).
See this image and copyright information in PMC

References

    1. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: multiorgan Transplantation. J Heart Lung Transplant 2018;37:1169–83. - PubMed
    1. Goldfarb SB, Hayes D Jr, Levvey BJ, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation.: twenty-first pediatric lung and heart–lung transplantation report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant 2018;37:1196–206. - PubMed
    1. Rossano JW, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: twenty-first pediatric heart transplantation report-2018; Focus theme: multiorgan Transplantation. J Heart Lung Transplant 2018;37:1184–95. - PubMed
    1. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation Report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant 2018;37:1155–68. - PubMed
    1. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant 2014;33:1009–24. - PubMed